Can HLA-G predict disease course in rheumatoid arthritis patients?

International Journal of Clinical Rheumatology

Volumn 8, Issue 6, 2013, Pages 627-638

  Rizzo, Roberta ^a   Bortolotti, Daria ^a   Baricordi, Olavio R ^a   Farina, Ilaria ^a   Padovan, Melissa ^a   Govoni, Marcello ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

biomarker; disease modifying antirheumatic drugs; early arthrtitis; HLA G; rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA G ANTIGEN; MESSENGER RNA; METHOTREXATE;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; BEHCET DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; FOLLOW UP; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INDEL MUTATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; PHARMACOGENETICS; POPULATION GENETICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERODERMA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84896961920     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.13.61     Document Type: Review

References (105)

1. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am. J. Med. 120(11), 936-939 (2007).
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 423(6937), 356-361 (2003).
3. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies of rheumatoid arthritis. Lancet 370(9602), 1861-1874 (2007).
4. Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat. Rev. Rheumatol. 9, 154-163 (2013).
5. Smolen JS, Aletaha D, Bijlsma JW et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631-637 (2010).
6. Aletaha D, Neogi T, Silman AJ et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569-2581 (2010).
7. Ishitani A, Geraghty D. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc. Nat. Acad. Sci. USA 89 (9), 3947-3951 (1992).
8. Apps R, Gardner L, Sharkey AM, Holmes N, Moffett A. A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur. J. Immunol. 37(7), 1924-1937 (2007).
9. Favier B, Ho Wang Yin KY, Wu J et al. Tolerogenic function of dimeric forms of HLA-G recombinant proteins: a comparative study in vivo. PLoS ONE 6(7), e21011 (2011).
10. Shiroishi M, Tsumoto K, Amano K et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc. Natl Acad. Sci. USA 100(15), 8856-8861 (2003).
11. Marchal-Bras-Goncalves R, Rouas-Freiss N, Connan F et al. A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc. 33(3), 2355-2359 (2001).
12. Caumartin J, Favier B, Daouya M et al. Trogocytosis-based generation of suppressive NK cells. EMBO J. 26(5), 1423-1433 (2007).
13. Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A. Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6 - STAT3 signaling pathway. Proc. Natl Acad. Sci. USA 105(24), 8357-8362 (2008).
14. Gregori S, Tomasoni D, Pacciani V et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 116(6), 935-944 (2010).
15. Kapasi K, Albert SE, Yie S, Zavazava N, Librach CL. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology 101(2), 191-200 (2000).
16. + CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 110(12), 3936-3948 (2007).
17. Du L, Xiao X, Wang C et al. Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells. Cancer Sci. 102 (7), 1272-1280 (2011).
18. Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M, Rey D, Moreau P. Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell. Mol. Life Sci. 68(3), 369-395 (2011).
19. Solier C, Mallet V, Lenfant F, Bertrand A, Huchenq A, Le Bouteiller P. HLA-G unique promoter region: functional implications. Immunogenetics. 53(8), 617-625 (2001).
20. Gobin SJ, Keijsers V, Cheong C, van Zutphen M, Van den Elsen PJ. Transcriptional regulation of HLA-G. Transplant Proc. 31(4), 1857-1859 (1999).
21. Gobin SJ, van Zutphen M, Woltman AM, van den Elsen PJ. Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. J. Immunol. 163(3), 1428-1434 (1999).
22. Lefebvre S, Berrih-Aknin S, Adrian F et al. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J. Biol. Chem. 276(9), 6133-6139 (2001).
23. Ibrahim EC, Morange M, Dausset J, Carosella ED, Paul P. Heat shock and arsenite induce expression of the nonclassical class I histocompatibility HLA-G gene in tumor cell lines. Cell. Stress Chaperones 5(3), 207-218 (2000).
24. Yie SM, Xiao R, Librach CL. Progesterone regulates HLA-G gene expression through a novel progesterone response element. Hum. Reprod. 21(10), 2538-2544 (2006).
25. Castelli EC, Mendes-Junior CT, Veiga-Castelli LC, Roger M, Moreau P, Donadi EA. A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. Mol. Biol. Evol. 28(11), 3069-3086 (2011).
26. Ober C, Billstrand C, Kuldanek S, Tan Z. The miscarriage-associated HLA-G -725G allele influences transcription rates in JEG-3 cells. Hum. Reprod. 21(7), 1743-1748 (2006).
27. Hviid TV, Hylenius S, Rorbye C, Nielsen LG. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 55(2), 63-79 (2003).
28. Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, Lindhard A, Baricordi OR. HLA-G and IL-10 in plasma in relation to HLA-G genotype and polymorphisms. Immunogenetics 56(3), 135-141 (2004).
29. Svendsen SG, Hantash BM, Zhao L et al. The expression and functional activity of membrane-bound human leukocyte antigen-G1 are influenced by the 3′-untranslated region. Hum. Immunol. 74(7), 818-827 (2013).
30. Yie SM, Li LH, Xiao R, Librach CL. A single base-pair mutation in the 3′-untranslated region of HLA-G mRNA is associated with pre-eclampsia. Mol. Hum. Reprod. 14(11), 649-653 (2008).
31. Tan Z, Randall G, Fan J et al. Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am. J. Hum. Genet. 81(4), 829-834 (2007).
32. Manaster I, Goldman-Wohl D, Greenfield C et al. MiRNA-mediated control of HLA-G expression and function. PLoS ONE 7(3), e33395 (2012).
33. Castelli EC, Moreau P, Oya e Chiromatzo A et al. In silico analysis of microRNAS targeting the HLA-G 3′ untranslated region alleles and haplotypes. Hum. Immunol. 70(12), 1020-1025 (2009).
34. Chang CC, Murphy SP, Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Hum. Immunol. 64(11), 1057-1063 (2003).
35. Mouillot G, Marcou C, Zidi I et al. Hypoxia modulates HLA-G gene expression in tumor cells. Hum. Immunol. 68(4), 277-285 (2007).
36. López AS, Alegre E, Le Maoult J, Carosella E, González A. Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Mol. Immunol. 43(14), 2151-2160 (2006).
37. Rizzo R, Hviid TV, Stignani M et al. The HLA-G genotype is associated with IL-10 levels in activated PBMCs. Immunogenetics 57(3-4), 172-181 (2005).
38. Bamberger AM, Jenatschke S, Schulte HM, Löning T, Bamberger MC. Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J. Clin. Endocrinol. Metab. 85(10), 3932-3936 (2000).
39. Rizzo R, Rubini M, Govoni M et al. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet. Genomics 16(9), 615-623 (2006).
40. Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 92(2), 369-376 (2001).
41. Lefebvre S, Moreau P, Guiard V et al. Molecular mechanisms controlling constitutive and IFN-gamma-inducible HLA-G expression in various cell types. J. Reprod. Immunol. 43(2), 213-224 (1999).
42. Le Maoult J, Caumartin J, Daouya M et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 109(5), 2040-2048 (2007).
43. Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella ED, Le Maoult J. Trogocytosis-based generation of suppressive NK cells. EMBO J. 26(5), 1423-1433 (2007).
44. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, De Mars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 248(4952), 220-223 (1990).
45. Hara N, Fujii T, Yamashita T, Kozuma S, Okai T, Taketani Y. Altered expression of human leukocyte antigen G (HLA-G) on extravillous trophoblasts in preeclampsia: immunohistological demonstration with anti-HLA-G specific antibody '87G' and anti-cytokeratin antibody 'CAM5.2'. Am. J. Reprod. Immunol. 36(6), 349-358 (1996).
46. Yie SM, Li LH, Li YM, Librach C. HLA-G protein concentrations in maternal serum and placental tissue are decreased in preeclampsia. Am. J. Obstet. Gynecol. 191(2), 525-529 (2004).
47. Peng B, Zhang L, Xing AY, Hu M, Liu SY. The expression of human leukocyte antigen G and E on human first trimester placenta and its relationship with recurrent spontaneous abortion. Sichuan Da Xue Xue Bao Yi Xue Ban 39(6), 976-979 (2008).
48. Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum. Immunol. 64(11), 1039-1044 (2003).
49. Mallet V, Blaschitz A, Crisa L et al. HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83+ dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Int. Immunol. 11(6), 889-898 (1999).
50. Blaschitz A, Lenfant F, Mallet V et al. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur. J. Immunol. 27(12), 3380-3388 (1997).
51. Rizzo R, Andersen AS, Lassen MR et al. Soluble human leukocyte antigen-G isoforms in maternal plasma in early and late pregnancy. Am. J. Reprod. Immunol. 62(5), 320-338 (2009).
52. Rebmann V, Busemann A, Lindemann M, Grosse-Wilde H. Detection of HLA-G5 secreting cells. Hum Immunol. 64(11), 1017-1024 (2003).
53. Derrien M, Pizzato N, Dolcini G et al. Human immunodeficiency virus 1 downregulates cell surface expression of the non-classical major histocompatibility class I molecule HLA-G1. J. Gen. Virol. 85(Pt 7), 1945-1954 (2004).
54. Matte C, Lajoie J, Lacaille J, Zijenah LS, Ward BJ, Roger M. Functionally active HLA-G polymorphisms are associated with the risk of heterosexual HIV-1 infection in African women. AIDS 18(3), 427-431 (2004).
55. Onno M, Pangault C, Le Friec G, Guilloux V, André P, Fauchet R. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J. Immunol. 164(12), 6426-6434 (2000).
56. Donaghy L, Gros F, Amiot L et al. Elevated levels of soluble non-classical major histocompatibility class I molecule human leucocyte antigen (HLA)-G in the blood of HIV-infected patients with or without visceral leishmaniasis. Clin. Exp. Immunol. 147(2), 236-240 (2007).
57. Rouas-Freiss N, Moreau P, Menier C, Le Maoult J, Carosella ED. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Cancer Biol. 17(6), 413-321 (2007).
58. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: are they clinically relevant? Cancer Biol. 17(6), 469-479 (2007).
59. Crispim, JC, Duarte, RA, Soares CP et al. Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transpl. Immunol. 18(4), 361-367 (2008).
60. Sebti Y, Le Maux A, Gros F et al. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br. J. Haematol. 138(2), 202-212 (2007).
61. Lila N, Carpentier A, Amrein C, Khalil-Daher I, Dausset J, Carosella ED. Implication of HLA-G molecule in heart-graft acceptance. Lancet 355(9221), 2138 (2000).
62. Lila N, Amrein C, Guillemain R et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 105(16), 1949-1954 (2002).
63. Qiu J, Terasaki PI, Miller J, Mizutani K, Cai J, Carosella ED. Soluble HLA-G expression and renal graft acceptance. Am. J. Transplant. 6(9), 2152-2156 (2006).
64. Fainardi E, Rizzo R, Melchiorri L et al. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol. 192(1-2), 219-225 (2007).
65. Rizzo R, Hviid TVF, Govoni M et al. HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. Tissue Antigens 71(6), 520-529 (2008).
66. Lee HM, Sugino H, Aoki C et al. Abnormal networks of immune response-related molecules in bone marrow cells from patients with rheumatoid arthritis as revealed by DNA microarray analysis. Arthritis Res. Ther. 13(3), R89 (2011).
67. Bakir-Gungor B, Sezerman OU. A new methodology to associate SNPs with human diseases according to their pathway related context. PLoS ONE 6(10), e26277 (2011).
68. Veit TD, Vianna P, Scheibel I et al. Association of the HLA-G 14-bp insertion/deletion polymorphism with juvenile idiopathic arthritis and rheumatoid arthritis. Tissue Antigens 71(5), 440-446 (2008).
69. Kim SK, Chung JH, Kim DH, Yun DH, Hong SJ, Lee KH. Lack of association between promoter polymorphisms of HLA-G gene and rheumatoid arthritis in Korean population. Rheumatol. Int. 32(2), 509-512 (2012).
70. Verbruggen LA, Rebmann V, Demanet C, De Cock S, Grosse-Wilde H. Soluble HLA-G in rheumatoid arthritis. Hum. Immunol. 67(8), 561-567 (2006).
71. Prigione I, Penco F, Martini A, Gattorno M, Pistoia V, Morandi, F. HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology 50(5), 966-972 (2011).
72. Le Maoult J, Le Discorde M, Rouas-Freiss N et al. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 62(4), 273-284 (2003).
73. Ongaro A, Stignani, M, Pellati A et al. Human leukocyte antigen-G molecules are constitutively expressed by synovial fibroblasts and upmodulated in osteoarthritis. Hum. Immunol. 71(4), 342-350 (2010).
74. Kuroki K, Hirose K, Okabe Y et al. Maenaka K. The long-term immunosuppressive effects of disulfide-linked HLA-G dimer in mice with collagen-induced arthritis. Hum. Immunol. 74(4), 433-438 (2013).
75. Stamp LK, O'Donnell JL, Chapman PT, Barclay, ML, et al. Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis. Ann. Rheum. Dis. 68(1), 154-155 (2009).
76. Kooloos WM, Wessels JA, van der Straaten T, Allaart CF, Huizinga TW, Guchelaar HJ. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 11(2), 163-175 (2010).
77. Rizzo R, Farina I, Bortolotti D et al. HLA-G may predict the disease course in patients with early rheumatoid arthritis. Hum. Immunol. 74(4), 425-432 (2013).
78. Needleman BW. Immunologic aspects of scleroderma. Curr. Opin. Rheumatol. 4(6), 862-868 (1992).
79. Wastowski IJ, Sampaio-Barros PD, Amstalden EM et al. HLA-G expression in the skin of patients with systemic sclerosis. J. Rheumatol. 36(6), 1230-1234 (2009).
80. Rosado S, Perez-Chacon G, Mellor-Pita S et al. Expression of human leukocyte antigen-G in systemic lupus erythematosus. Hum. Immunol. 69(1), 9-15 (2008).
81. Chen J, Shen B, Jiang Y et al. Analysis of immunoglobulin-like transcripts (ILTs) in lymphocytes with sHLA-G and IL10 from SLE patients. Clin. Exp. Med. 13(2), 135-142 (2013).
82. Rizzo R, Hviid TV, Govoni M et al. HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. Tissue Antigens. 71(6), 520-529 (2008).
83. Rudstein-Svetlicky N, Loewenthal R, Horejsi V, Gazit E. HLA-G levels in serum and plasma. Tissue Antigens. 69(2), 140-142 (2007).
84. Monsiváis-Urenda AE, Baranda L, Alvarez-Quiroga C, Abud-Mendoza C, González-Amaro R. Expression and functional role of HLA-G in immune cells from patients with systemic lupus erythematosus. J. Clin. Immunol. 31(3), 369-378 (2011).
85. Fernando MM, Freudenberg J, Lee A et al. Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G. Ann. Rheum. Dis. 71(5), 777-784 (2012).
86. Veit TD, Cordero EA, Mucenic T et al. Association of the HLA-G 14 bp polymorphism with systemic lupus erythematosus. Lupus 18(5), 424-430 (2009).
87. Pedroza LS, Sauma MF, Vasconcelos JM et al. Systemic lupus erythematosus: association with KIR and SLC11A1 polymorphisms, ethnic predisposition and influence in clinical manifestations at onset revealed by ancestry genetic markers in an urban Brazilian population. Lupus 20(3), 265-273 (2011).
88. Consiglio CR, Veit TD, Monticielo OA et al. Association of the HLA-G gene +3142C>G polymorphism with systemic lupus erythematosus. Tissue Antigens 77(6), 540-545 (2011).
89. Park KS, Nam J, Lee ES, Choi JS, Bang D, Lee S. Increased risk of human leukocyte antigen-G gene variants in Behçet's disease. Clin. Exp. Rheumatol. 24(5 Suppl. 42), S126-S127 (2006).
90. Park KS, Park JS, Nam JH, Bang D, Sohn S, Lee ES. HLA-E*0101 and HLA-G*010101 reduce the risk of Behcet's disease. Tissue Antigens 69(2), 139-144 (2007).
91. Kim JJ, Hong SJ, Hong YM et al. Genetic variants in the HLA-G region are associated with Kawasaki disease. Hum. Immunol. 69(12), 867-871 (2008).
92. Rossman MD, Thompson B, Frederick M et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am. J. Hum. Gen. 73(4), 720-735 (2003).
93. Hviid TV, Milman N, Hylenius S, Jakobsen K, Jensen MS, Larsen LG. HLA-G polymorphisms and HLA-G expression in sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 23(1), 30-37 (2006).
94. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 373, 659-672 (2009).
95. Naredo E, Bonilla G, Gamero F, Uson J, Carmona L, Laffon A. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann. Rheum. Dis. 64, 375-381 (2005).
96. Brenol CV, Veit TD, Chies JA, Xavier RM. The role of the HLA-G gene and molecule on the clinical expression of rheumatologic diseases. Rev. Bras. Reumatol. 52(1), 75-91 (2012).
97. Kawashiri SY, Kawakami A, Iwamoto N et al. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis. Rheumatology (Oxford) 50, 962-965 (2011).
98. Wu CC, Wu TC, Liu FL, Sytwu HK, Chang DM. TNF-α inhibitor reverse the effects of human umbilical cord-derived stem cells on experimental arthritis by increasing immunosuppression. Cell. Immunol. 273(1), 30-40 (2012).
99. Wang L, Wang L, Cong X, Liu G, Zhou J. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev. doi:10.1089/scd.0023 (2013) (Epub ahead of print).
100. Boyson JE, Erskine R, Whitman MC et al. Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc. Natl Acad. Sci. USA 99(25), 16180-16185 (2002).
101. Morales PJ, Pace JL, Platt JS, Langat DK, Hunt JS. Synthesis of beta(2)-microglobulin-free, disulphide-linked HLA-G5 homodimers in human placental villous cytotrophoblast cells. Immunology 122(2), 179-188 (2007).
102. Morales PJ, Pace JL, Platt JS et al. Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype. J. Immunol. 171(11), 6215-62124 (2003).
103. Zilberman S, Schenowitz C, Agaugué S et al. HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment. Eur. J. Immunol. 42(6), 1599-1608 (2012).
104. Online Mendelian Inheritance in Man. www.omim.org
105. IMGT/HLA. www.ebi.ac.uk/ipd/imgt/hla